Search

everythinglearnresearchcommunity

for

Search:↓

A user with diffuse hair loss for a decade tried various treatments, including LLLT Helmet, supplements, topicals, and hair transplants. They found relief from scalp inflammation and itching using a topical solution made from crushed Xeljanz pills mixed with ethyl alcohol.

A 20-year-old woman with androgenetic alopecia feels depressed about her hair loss, despite using topical minoxidil, spironolactone, and saw palmetto. Suggestions include trying oral minoxidil, higher doses of finasteride or dutasteride, and checking for vitamin deficiencies and heavy metal exposure.

The user is taking 2.5 mg dutasteride and 5% minoxidil but is not seeing hair regrowth, and is considering adding RU58841. They are experiencing fatigue and low MCV/MCH, possibly related to dutasteride, and are advised to be patient, consider microneedling, and check for iron deficiency.

A 24-year-old male experienced hair loss despite using minoxidil and finasteride, later switching to dutasteride, higher-dose minoxidil, iron supplements, and derma stamping, which initially improved his condition. However, after moving to a stressful environment and undergoing minor surgery, his hair loss rapidly increased, particularly on one side of his temple.

The conversation discusses using Tretinoin for treating androgenic alopecia. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.

The user is using a combination of 7% minoxidil, 0.2% finasteride, 0.5mg finasteride, RU58841, and daily microneedling but is not seeing hair regrowth after 5 months. Suggestions include being patient, reducing microneedling frequency, considering oral minoxidil, and possibly switching to dutasteride if no improvement after a year.

The conversation discusses hair regrowth progress from Norwood scale 4 to 2.5 over a year using daily 8.5-9% RU58841, topical Dutasteride 0.1%, RU58841 5% 1.5 times a week, and daily caffeine redensyl scalp treatment.

Dr. Bloxham's 9-month update on FUT scar revision with Verteporfin shows promising results. Excitement is high for FUE, which appears highly effective based on Dr. Barghouthi's findings.

RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.

The user is experiencing severe hair thinning and is using multiple treatments including topical finasteride, minoxidil, tretinoin, latanoprost, oral minoxidil, dutasteride, saw palmetto, and derma wounding. They are considering adding RU58841 and are contemplating a hair transplant and exosomes due to frustration with current results.

Low Dose Naltrexone (LDN) may reduce inflammation in alopecia conditions. It is discussed as a potential adjunct treatment with finasteride or dutasteride for androgenic alopecia.

A user is upset about hair loss due to seborrheic dermatitis and DUPA, which prevents a hair transplant. They mention using jojoba oil and discuss treatments like Minoxidil, finasteride, and RU58841.

A 24-year-old woman experiencing hair loss due to low ferritin and iron deficiency is advised to correct these deficiencies before considering minoxidil. Minoxidil is not recommended for temporary hair loss caused by iron deficiency.

A user lost 60% hair density in 4 months, started finasteride and microneedling, and has greasy, flaky, yellowish scalp. They are awaiting biopsy results, and another user suggested trying ketoconazole shampoo.

GT20029 is discussed as a potential treatment for androgenetic hair loss by targeting androgen receptors, unlike finasteride which reduces DHT broadly. Concerns include its effectiveness, genetic variations in androgen receptors, and availability, with some skepticism about its potential as a true alternative.

The user was rejected from participating in a clinical trial for an extended-release oral Minoxidil due to having rheumatoid arthritis, despite initially being accepted. They had stopped using Dutasteride and Minoxidil to qualify but continued using other treatments like RU58841 and red light therapy.

The user experienced worsening hair density despite using finasteride, minoxidil, dutasteride, and RU58841, with some temporary improvement after stopping RU58841. Currently, they are on 2.5mg dutasteride daily and topical minoxidil, but continue to struggle with hair density issues.

GT20029 shows promising results for hair loss treatment, with potential approval in China by 2026 or 2027, but U.S. approval may take longer. It could serve as an alternative to finasteride, with a potentially better side effect profile.

The user has high DHT levels despite using dutasteride, which may not be effective due to potential damage or spoilage. They are considering a hair transplant if DHT levels don't decrease after two years.

The user is using a hair loss treatment regimen that includes RU58841, minoxidil mixed with finasteride, adenosine, dermarolling with lidocaine cream, and biotin. They are questioning if they are dermarolling too aggressively and are willing to accept baldness if no improvement is seen in 6 months.

The user has been using finasteride for almost a year, starting at age 18, and added tretinoin and 5% topical minoxidil 1-2 months ago. They are concerned about hair receding again despite the treatments.

A 30-year-old male is experiencing hair loss and is concerned about his receding hairline, seeking advice on his Norwood scale classification. He is apprehensive about using Minoxidil and finasteride as treatments.

The user started taking zinc for a deficiency and is discussing one month of progress. They are inquiring if the observed changes indicate hair regrowth.

An 18-year-old male has been using finasteride for 11 months, minoxidil since September, dutasteride weekly, chelated iron supplements, and derma rolling, but his hair loss has worsened. He switched finasteride brands from Finalo and Finbald, and is concerned about decreased hair density.

The conclusion of the conversation is that the user should consider using treatments such as finasteride, minoxidil, and RU58841 to potentially reverse their hair loss. Other suggestions include using hair loss concealers and maintaining a healthy diet.

The conversation is about the potential of SCUBE3 to regrow a juvenile hairline. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.

Clascoterone, a topical anti-androgen, is generating interest for potentially fewer systemic side effects. Users are curious about its effectiveness and details like concentration and duration of use.

The user is experiencing severe hair shedding after using RU58841, stemoxydine, and minoxidil, and has stopped using finasteride due to side effects. They hope the shedding is temporary and will lead to regrowth.

The user has been experiencing hair loss for over 5 years and is currently using a topical treatment of finasteride, minoxidil, and tretinoin, along with derma rolling and a hair growth oil. They have previously tried oral finasteride, pyrithione zinc, RU58841, and dutasteride, but are seeking advice on whether to retry dutasteride or find a more reliable source for RU58841 due to ongoing hair density loss.

ET-02, a new hair loss treatment, shows promising results with a 6-fold increase in hair count, potentially outperforming minoxidil by activating stem cells in hair follicles. Further trials are ongoing to confirm its efficacy and safety, with potential market release in the future.